The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer-Reference-Cited by-同舟云学术

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer

Published:2017-06-13 Issue:18 Volume:123 Page:3532-3539
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pomerantz Mark M.¹^ORCID,Spisák Sandor¹,Jia Li²,Cronin Angel M.³,Csabai Istvan⁴,Ledet Elisa⁵,Sartor A. Oliver⁵,Rainville Irene³,O'Connor Edward P.¹,Herbert Zachary T.¹,Szállási Zoltan⁶,Oh William K.⁷,Kantoff Philip W.⁸,Garber Judy E.³,Schrag Deborah³,Kibel Adam S.²,Freedman Matthew L.¹

Affiliation:

1. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

2. Department of Surgery, Division of Urology; Brigham and Women's Hospital; Boston Massachusetts

3. Division of Population Sciences; Dana-Farber Cancer Institute; Boston Massachusetts

4. Department of Physics of Complex Systems Eotvos Lorand University; Budapest Hungary

5. Department of Medicine; Tulane Cancer Center; New Orleans Louisiana

6. Department of Pediatrics; Boston Children's Hospital; Boston Massachusetts

7. Department of Medicine, Division of Hematology and Oncology; Tisch Cancer Institute; New York New York

8. Department of Medicine; Memorial Sloan Kettering Cancer Institute; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Cancer risks in BRCA2 mutation carriers;Breast Cancer Linkage Consortium;J Natl Cancer Inst.,1999

2. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary;Asperen;J Med Genet.,2005

3. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients;Kote-Jarai;Br J Cancer.,2011

4. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer;Gallagher;Clin Cancer Res.,2010

5. Prostate cancer progression and survival in BRCA2 mutation carriers;Tryggvadottir;J Natl Cancer Inst.,2007

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience;Cancers;2024-01-09

2. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy;Clinical Genitourinary Cancer;2024-01

3. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?;Cancer Chemotherapy and Pharmacology;2023-11-07

4. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis;Urologic Oncology: Seminars and Original Investigations;2023-11

5. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?;Critical Reviews in Clinical Laboratory Sciences;2023-10-26